In a chronic myeloid leukaemia cell line (K562), the enhancer for TET3 was identified as a strong target for HIF1α binding, with TET3 expressed at higher levels than TET1 and TET2 in hypoxia [187]. Here, TET3 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.